

0400 1714

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Ed Schuler et al

Serial No: 09/811,754 ✓

Filing Date: March 19, 2001

Title: Use of Streptomyces Hyalurolyticus
Enzyme in Ophthalmic Treatments

Attorney Docket No: GC-425

Examiner:

Group Art Unit:

#2
5-17-01

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231


STATEMENT UNDER 37 CFR 1.97(e)

Sir:

The undersigned hereby certifies that either:

- () Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, not more than three months prior to the filing of the statement, or
- (X) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or
- () to the knowledge of the undersigned, after making reasonable inquiry, was known to an individual designated in 37 CFR 1.56 (c) more than three months prior to the filing of the Information Disclosure Statement.

Respectfully Submitted,



Sheldon H. Parker
Attorney/Agent for Applicant(s)
Reg. No.: 20,738

Date: April 23, 2001

Telephone No.: 804-817-6606

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: April 23, 2001

Typed Name: Mistie Dyke

Signature: 



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ed Schuler et al	
Serial No: 09/811,754	Group Art Unit:
Filing Date: March 19, 2001	
Title: Use of Streptomyces Hyalurolyticus Enzyme in Ophthalmic Treatments	Examiner:
Attorney Docket No.: GC-425	

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
MAY -4 2001
TC 1700 MAIL ROOM

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

- ☒ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either a:
☐ Certification under 37 CFR 1.97(e), or
☐ a \$240.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with a:
☐ Certification under 37 CFR 1.97(e), and
☐ a petition under 37 CFR 1.97(d)(2)(ii), and
☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)


☒ Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,



✓ Sheldon H. Parker
Attorney/Agent for Applicant(s)
Reg. No. 20,738

Date: April 23, 2001

Telephone No.: 804-817-6606

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: April 23, 2001

Typed Name: Mistie Dyke

Signature:

